The inflow and outflow of anti-glaucoma drugs.
The treatment of glaucoma by reducing intraocular pressure has relied traditionally on inhibiting aqueous humor secretion (inflow). However, recent therapeutic approaches have targeted aqueous humor outflow. Prostanoid FP receptor agonists selectively increase uveoscleral outflow and the prostamide analog bimatoprost alters trabecular and uveoscleral outflow. An emerging therapeutic strategy is direct neuroprotection of retinal ganglion cells, which are selectively lost in glaucoma.
Woodward
David F
DF
Department of Biological Sciences, Allergan, Irvine, CA 92612, USA.
Gil
Daniel W
DW
D000322:Adrenergic Agonists / Q000627:therapeutic use*; D018674:Adrenergic Antagonists / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism; D005123:Eye / Q000033:anatomy & histology* / Q000187:drug effects; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*
D000322:Adrenergic Agonists; D018674:Adrenergic Antagonists